TransMedics (TMDX) Net Income towards Common Stockholders (2018 - 2026)

TransMedics' Net Income towards Common Stockholders history runs 9 years deep, the most recent figure standing at $7.3 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 71.51% year-over-year to $7.3 million in Q1 2026; TTM through Mar 2026 was $191.4 million, a 1303.48% increase from a year earlier, with the FY2025 full-year figure at $190.3 million, up 130257.53% from the prior year.
• Net Income towards Common Stockholders slipped to $7.3 million in Q1 2026 per TMDX's latest filing, from $124.9 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $124.9 million in Q4 2025 and bottomed at -$28.4 million in Q4 2024.
• The 5-year median for Net Income towards Common Stockholders is $2.0 million (2023), against an average of $9.1 million.
• Biggest YoY gain for Net Income towards Common Stockholders was 1318.18% in 2024; the steepest drop was 1525.1% in 2024.
• Year by year, Net Income towards Common Stockholders stood at -$6.7 million in 2022, then surged by 129.7% to $2.0 million in 2023, then plunged by 1525.1% to -$28.4 million in 2024, then jumped by 539.21% to $124.9 million in 2025, then tumbled by 94.14% to $7.3 million in 2026.
• Per Business Quant, the three latest TMDX Net Income towards Common Stockholders figures stand at $7.3 million (Q1 2026), $124.9 million (Q4 2025), and $24.3 million (Q3 2025).